News Channels

13 May 2017 Capricor Therapeutics Provides Update on ALLSTAR Trial
13 May 2017 First study of Oncolytic HSV-1 in children and young adults with cancer indicates safety, tolerability
13 May 2017 AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice (GCP) standards
13 May 2017 Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
13 May 2017 Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
12 May 2017 Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial for Stage III unresectable lung cancer
11 May 2017 VBL Therapeutics Presents Data on VB-111 in Combination with Checkpoint Inhibitor at the 20th Annual ASGCT Meeting
11 May 2017 AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked Retinitis Pigmentosa at the American Society of Gene and Cell Therapy 20th Annual Meeting
11 May 2017 Orphazyme completes enrolment of patients for phase 3 clinical trial in Niemann-Pick type C disease
11 May 2017 Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia
11 May 2017 Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia
11 May 2017 SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection
11 May 2017 DNAtrix Oncolytic Myxoma Virus Eliminates Treatment-Resistant Cancer
11 May 2017 Peloton Therapeutics Initiates Patient Dosing in Phase 2 Study of PT2385 for von Hippel-Lindau Disease-Associated Kidney Cancer
11 May 2017 Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
11 May 2017 Astellas Announces Decision to Discontinue ASP8273 Treatment and Close Randomization for Clinical Study Protocol 8273-CL-0302
11 May 2017 Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
11 May 2017 Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim
11 May 2017 Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy
11 May 2017 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top